| Deputy Head, Therapeutic Innovations and Early Trials Department (DITEP), Gustave Roussy, France Professor & Medical Oncologist Bladder Cancer Oncology Commitee, Gustave Roussy, France Professor Yohann Loriot is a university professor – hospital practitioner, medical oncologist specializing in the management of bladder cancer. At Gustave Roussy, he serves as deputy head of the department of therapeutic innovations and early trials (DITEP) and coordinates the UNLOCK program for analyzing the mechanisms of action and resistance to innovative therapies. He teaches medicine at Paris-Saclay University. Holder of a doctorate in medicine from Pierre-et-Marie-Curie University as well as a doctorate in science in anti-tumor pharmacology from the University of Paris-Saclay, he obtained his authorization to direct research in 2024. He joined Gustave Roussy in 2009, and spent a year at the Vancouver Prostate Centre, a research center attached to the University of British Columbia in Canada, to study the mechanisms of resistance to therapies targeting the androgen receptor. In 2013, he received the Conquer Cancer Foundation ASCO Young Investigator Award. Alongside his healthcare activities, Professor Loriot devotes his research activities to the analysis of treatment resistance mechanisms in solid cancers (UNLOCK program), the identification of therapeutic targets and the development of new drugs, particularly in prostate and urothelial cancers, as well as the development of preclinical models. His work has been the subject of more than 300 publications in scientific journals, such as the New England Journal of Medicine. He is a member of several learned societies, such as ESMO, ASCO and AACR, and is responsible for European recommendations for the management of bladder tumors. Finally, he leads the urological tumors research group at the EORTC. |